RE:RE:RE:RE:RE:RE:RE:Italy The IV push trial costing $2M could be a good reference as per the cost of the IM trial which THTX has to cover now I think in terms of patients compliance or new patients starting the treatment the IM is much more patient friendly so that extra $2M to me is worth the investment. As per competition I think the company has to use the long lasting efficacy almost a decade now to market the drug also their pricing is higher than the competition so they should either offer more discounts or more promotions.
SPCEO1 wrote: If it is only a 13% discount, that is better than I would have expected. Actually much better. And since the deceline in US sales of Trogarzo has been faster than I expected, that is very helpful as TH tries to hold the line with Trogarzo total sales. Previously, I thought Trogarzo sales in the US would fall off only marginally and that total Trogarzo sales would grow. Now I am not as confident in that a s US Trogarzo sales seem to have been hit harder than I was expecting by Viiv. With new competition from GILD on the horizon as well, the outlook is not great for Trogarzo. The more MDR drug options there are, the greater the chance a patient will be willing to move to a pill from an injection since by abandoning Trogarzo, their body will likely develop a resistance to it. I was counting on that to keep all the Trogarzo patients TH could accumulate before Viiv's pill hit the market in place, but it looks like some patients are willing to give up one of the few (sometimes only) treatments that is working for them for the convenience of a pill.
I can't see the IV Push helping a whole lot with both Viiv and soon GILD offering pill options and wonder why TH is even bothering to pursue the IM version. Seems like there is a good chance any money spent on the IM version by TH is not going to get a great return.
That same competition will be undermining Trogarzo in Europe as well. TH apparently has about 20 people working out of Ireland supporting one small drug with some difficult competition on the horizon. Perhaps the idea is to build a European presence so they are ready if TH-1902 zips through to approval quickly, as it might. But one has to wonder about the ROI on Europe right now. Maybe there is a bigger plan that we are presently unaware of to get more drugs for Europe to sell in the meantime, but it seems to me that TH may be outrunning its headlights in Europe. From what I can see competitively, the most sensible approach to Trogarzo right now would be to milk as much cash flow from it as possible and not invest more in it.
scarlet1967 wrote:
Wino115 wrote: I think we can go with Paul's "...it was a good price..." ! Certainly not US levels, but probably not below 50%. It had always sounded to me like they thought they could get 75-80% of US price and the Viiv product provided a bit of an umbrella to that as well.
SPCEO1 wrote: I think I will need to hire an Italian lawyer to actually figure out what the annual revenues from one Italian patient on Trogarzo for a year might be! They also mentioned discounts but it is not clear to me what those discounts might be and there seemed to be other circumstances that might impact the price. But figuring all that out seems like a lot of work and that you need to know someone familiar with Italian drug pricing to get an accurate answer.
scarlet1967 wrote: "packaging: «200 mg - concentrate for solution for infusion -
intravenous use - vial (glass) - 1.33 ml (150 mg / ml) »2
vials - AIC n. 048255018 / E (base 10);
reimbursement class: H;
ex factory price (excluding VAT): euro 2,000.00;
retail price (VAT included): € 3,300.80.”
I don’t know what the reimbursement H class means versus retail price but 2000 euros equals US $2328. Compared with the US pricing excluding VAT(tax in Italy 22%) it seems it’s about 13% cheaper in Italy.
“The cost for Trogarzo intravenous solution (200 mg/1.33 mL) is around $2,671 for a supply of 2.66 milliliters.
The annual list price for every two-week infusions is $118,000.”